INTRODUCTION
In New Zealand, the presence of the biomarker human epidermal growth factor receptor 2 (HER2) in women with breast cancer has been commonly ascertained since 1998, and routinely since 2006.
It has been found to be present in approximately 15-20% of breast cancers, 1,2 presenting more commonly in breast cancers of younger women. 3 PHARMAC, the national pharmaceutical funding agency. 9, 10 In 2006, 12 months of adjuvant therapy was licensed by the FDA for the treatment of stage I-III HER2+ve breast cancer. 11 In July 2007, PHARMAC also approved trastuzumab for stage I-III breast cancer but only funded 9 weeks of treatment. 10 From 1 July 2010, trastuzumab was funded for early-stage disease for treatment of up to 12 months. 12 Trastuzumab for stage I-III HER2+ve breast cancer is only funded in conjunction with chemotherapy, either concomitantly with taxane chemotherapy or sequentially after chemotherapy.
Stage I breast cancer generally has an excellent prognosis. As the early adjuvant trastuzumab breast trials included only patients with stage I HER2+ve cancers more than 1 cm in size, guidelines for adjuvant treatment with trastuzumab may not apply to stage I HER2+ve tumors smaller than 1 cm. 6, 13 Stage II and III HER2+ve breast cancers are associated with a progressively poorer prognosis and greater risk of recurrence and these women should be offered trastuzumab as part of their adjuvant therapy, 4, 5 as should women with metastatic HER2+ve breast cancers.
This study aims to (1) ascertain the patterns of use of trastuzumab in women with invasive HER2+ve breast cancer in New Zealand and (2) compare clinical outcomes between women with stage I-III HER2+ve breast cancer who received adjuvant trastuzumab versus those who did not.
METHODS

Data source
The In the Cox proportional hazards model, hazard ratios between the chemotherapy-only group and the trastuzumab-treated group were estimated after adjustment for age, ethnicity, comorbidity (we applied a C3 score retrospectively to breast cancer patients 14 
Pattern of trastuzumab use in HER2+ve invasive breast cancers
Outcomes in women treated with 9 weeks and 12 months of trastuzumab
Trastuzumab is expensive and not without side effects. If a shorter treatment is equivalent with regard to outcomes, then it will be more 
TA B L E 1 The treatment pattern of trastuzumab in HER2+ve breast cancers
Outcomes in women with HER2+ve stage I-III breast cancer treated with trastuzumab
Of the 1455 women with HER2+ve stage I-III breast cancer, 27 developed metastatic disease or local recurrence in less than 3 months of initial diagnosis, 2 had inflammatory breast cancer, 185 had a tumor size less than 10 mm and 103 women were 75+ years old (Figure 1) . These 317 women were excluded from further analyses. A total of 275 women who received chemotherapy without trastuzumab TA B L E 2 Characteristics of women in the chemotherapy-only group and women in the trastuzumab-treated group for their primary breast cancer within 12 months of cancer diagnosis were included in the chemotherapy-only group, and 604 women who received chemotherapy and trastuzumab were included in the trastuzumab-treated group. The rest of women were not included either because they did not start chemotherapy for primary breast cancer in no more than 12 months of initial diagnosis (237), or because they started trastuzumab in more than 12 months of initial diagnosis 18 or the start date of trastuzumab was not available. 4 Over 90% women in the chemotherapy-only group were diagnosed Anthracycline-based chemotherapy was more commonly used in the early years, and anthracycline-and taxane-based chemotherapy was more commonly used in recent years (Table A1 ).
The median follow-up time was 107 months for women in the chemotherapy-only group and 53 months for women in the trastuzumab-treated group. Breast cancer-specific survival, all-cause survival and metastases-free survival in the trastuzumab-treated group were all significantly better (log-rank test: P values all less than 0.001) (Figure 2 , Table A2 ). The unadjusted hazard ratios in 
Outcomes in women treated with 9 weeks and 12 months of trastuzumab
Women (175) who received 9 weeks of trastuzumab were older and diagnosed in earlier years than women (342) who received 12 months of trastuzumab (Table A3 ). There were no significant differ- 4 We have shown that during this time, there has also been a TA B L E 3 Hazard ratios in the trastuzumab-treated group compared to the chemotherapy-only group estimated with Cox proportional hazards model This may be because our study was underpowered to show a difference and further research is needed to demonstrate whether there is a worthwhile benefit of 12 months treatment over 9 weeks. A 9-week course of trastuzumab is associated with a smaller risk of side effects and lower costs. 16, 17 but if this regime is significantly less effective, then the 12 month course should be preferred. The results of the SOLD trial, which has been powered to compare 9 weeks with 12 months of trastuzumab, are eagerly awaited. 18 The strength of this study is that it is based on real-world data. The patients in clinical trials are highly selected and may not represent the diversity of patients who may benefit from trastuzumab. This study is based on the Waikato and Auckland population-based Breast Cancer
Registers that collect good quality data on all breast cancer patients.
The data have been shown to be highly complete and accurate. 19 The limitations of this study are associated with the nature of an observational study. The characteristics of patients in the chemotherapy-only group and those in the trastuzumab-treated group are not evenly distributed. Although we adjusted for a number of factors in the multivariate analyses, there may be still some residual confounding. However, our findings are in line with the large randomized trials [4] [5] [6] [7] [8] and support the belief that the use of trastuzumab has significant benefit for women with HER2+ve breast cancer.
CONCLUSIONS
Overall, this observational study has shown a substantial improvement in survival for women with HER2+ve stage I-III breast cancer, and this improvement can be attributed to the treatment of trastuzumab.
Changes in chemotherapy also appear to have led to improved outcomes. Further research is needed to establish the benefit of 12 months treatment of trastuzumab over 9 weeks.
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